| Attribute | Value | [1]
|----------|-------|
| Symbol | RPL19 |
| Name | Ribosomal Protein L19 |
| Chromosome | 17q12 |
| NCBI Gene ID | 6143 |
| UniProt ID | P84098 |
RPL19 encodes Ribosomal Protein L19, a component of the large (60S) ribosomal subunit. As part of the ribosome, RPL19 plays a critical role in protein synthesis and translational regulation [2]. RPL19 is one of the most abundant ribosomal proteins and is essential for eukaryotic cell viability [3].
Beyond its canonical role in translation, RPL19 has been implicated in various extra-ribosomal functions including:
RPL19 dysregulation has been reported in Alzheimer's disease (AD) brains. Studies have shown altered expression of ribosomal proteins, including RPL19, in AD hippocampal tissue compared to age-matched controls [7]. The downregulation of ribosomal proteins contributes to impaired protein synthesis in AD neurons, a hallmark of the disease pathogenesis [8].
In Parkinson's disease (PD), RPL19 has been identified as a differentially expressed gene in dopaminergic neurons. Research using post-mortem brain tissue has revealed alterations in ribosomal protein expression that may contribute to neuronal vulnerability [9].
RPL19 mutations have been associated with rare cases of familial ALS. These mutations affect ribosomal function and lead to defects in protein homeostasis, a central mechanism in ALS pathogenesis [10].
The ribosome is increasingly recognized as a key player in neurodegenerative diseases. Key mechanisms include:
Global Translation Reduction: Neurodegenerative brains show decreased ribosomal protein expression, leading to impaired proteostasis [11]
Stress Granule Formation: Under cellular stress, ribosomal proteins including RPL19 can be sequestered into stress granules, disrupting normal translation [12]
Ribosome Biogenesis Defects: Impaired ribosome assembly contributes to neuronal death [13]
RPL19 is ubiquitously expressed in all tissues, with high expression in brain regions including:
Targeting ribosomal function represents a emerging therapeutic approach for neurodegenerative diseases:
Alzheimer's disease (AD) represents the most common cause of dementia worldwide, characterized by extracellular amyloid-beta plaques and intracellular neurofibrillary tangles composed of hyperphosphorylated tau protein. Beyond these hallmark pathologies, AD brains exhibit widespread ribosomal dysfunction that contributes to disease progression[18].
Studies have demonstrated that ribosomal dysfunction occurs early in AD pathogenesis, before significant neuronal loss[19]. Key observations include:
Synaptic dysfunction is considered the best correlate of cognitive decline in AD. RPL19 contributes to synaptic pathology through:
Parkinson's disease (PD) is characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta and the presence of Lewy bodies composed of aggregated alpha-synuclein.
Alpha-synuclein (SNCA) translation is modulated by ribosomal function:
ALS is characterized by progressive loss of upper and lower motor neurons. Ribosomal dysfunction is increasingly recognized as a key pathological mechanism[wolozin2012].
Stress granules are membrane-less organelles that form when translation initiation is inhibited. In ALS:
Motor neurons exhibit particular sensitivity to ribosomal stress due to:
The Integrated Stress Response is activated by ribosomal stress:
The mTOR pathway coordinates cell growth with nutrient and energy status:
The RQC pathway handles stalled ribosomes[23]:
Ribosomal proteins regulate p53 through MDM2:
The hippocampus shows high RPL19 expression, particularly in:
These regions are critical for memory formation and are vulnerable in AD.
In the cerebral cortex:
Dopaminergic neurons in the substantia nigra pars compacta express RPL19, and ribosomal dysfunction contributes to their selective vulnerability in PD.
Purkinje cells in the cerebellum show high RPL19 expression, reflecting their high protein synthesis requirements for motor coordination.
Crystal structure of the eukaryotic ribosome - Nature (2010). 2010. ↩︎
Essential ribosomal protein genes in yeast - Nature (1999). 1999. ↩︎
RPL19 regulates cell proliferation via p53 - Cell Cycle (2014). 2014. ↩︎
Ribosomal proteins as p53 interactors - Oncogene (2011). 2011. ↩︎
Ribosomal proteins in cellular stress response - J Cell Biol (2012). 2012. ↩︎
Altered ribosomal protein expression in AD brain - J Neurosci (2003). 2003. ↩︎
Translational dysregulation in AD - Nat Rev Neurosci (2011). 2011. ↩︎
Gene expression profiling in PD substantia nigra - Brain (2004). 2004. ↩︎
Ribosomal protein mutations in ALS - Neuron (2013). 2013. ↩︎
Ribosomal protein dysregulation in neurodegeneration - Trends Neurosci (2014). 2014. ↩︎
Stress granules and neurodegenerative disease - Nat Rev Neurol (2020). 2020. ↩︎
Ribosome biogenesis in neuronal survival - Autophagy (2021). 2021. ↩︎
Neuronal protein synthesis requirements - Neuron (2009). 2009. ↩︎
Ribosome-targeting drugs for neurodegeneration - Pharmacol Rev (2019). 2019. ↩︎
mTOR inhibition and neuroprotection - Nat Rev Drug Discov (2018). 2018. ↩︎ ↩︎
Gene therapy for ribosomal protein defects - Mol Ther (2022). 2022. ↩︎
Hernandez-Ortega K, et al. Altered ribosomal protein expression in AD brain. J Neuropathol Exp Neurol. 2016. ↩︎
Ding Q, et al. Ribosome dysfunction in early AD. J Neurosci. 2005. ↩︎
Liu Y, et al. Ribosome profiling in AD. Nat Neurosci. 2019. ↩︎
Pearson C, et al. Mitochondrial translation in neurodegeneration. J Clin Invest. 2018. ↩︎
De Keersmaeker K, et al. p53 activation in ribosomal stress signaling. Cell Cycle. 2017. ↩︎
Ishimura R, et al. Ribosome stalling and quality control. Nat Rev Neurol. 2014. ↩︎